28469263|t|Estrogen deficiency accelerates lumbar facet joints arthritis
28469263|a|Dramatic increase in the prevalence of lumbar facet joint (LFJ) arthritis in women around the age of menopause indicates a protective role for estrogen in LFJ arthritis. To date, there is no evidence for this indication and the mechanism of such an effect remains poorly understood. In this study, ovariectomized (OVX) mice were used to mimic the estrogen - deficient status of post-menopausal women. Micro-CT and immunohistochemistry was employed to assess the morphological and molecular changes in ovariectomy - induced LFJ arthritis. The results show that the LFJ subchondral bone mass was significantly decreased in OVX mice, with increased cavities on the interface of the subchondral bone. Severe cartilage degradation was observed in ovariectomy - induced LFJ arthritis. Increased blood vessels and innervations were also found in degenerated LFJ, particularly in the subchondral bone area. 17β-Estradiol treatment efficiently suppressed LFJ subchondral bone turnover, markedly inhibited cartilage degradation, and increased blood vessel and nerve ending growth in degenerated LFJ in OVX mice. Our study reveals that estrogen is a key factor in regulating LFJ metabolism. Severe LFJ degeneration occurs when estrogen is absent in vivo. Collapsed subchondral bone may be the initiation of this process, and estrogen replacement therapy can effectively prevent degeneration of LFJ under estrogen - deficient conditions.
28469263	0	8	Estrogen	T109,T121,T125	C0014939
28469263	9	19	deficiency	T169	C0011155
28469263	20	31	accelerates	T169	C0521110
28469263	32	51	lumbar facet joints	T030	C0507372
28469263	52	61	arthritis	T047	C0003864
28469263	71	79	increase	T169	C0442805
28469263	87	97	prevalence	T081	C0220900
28469263	101	119	lumbar facet joint	T030	C0507372
28469263	121	124	LFJ	T030	C0507372
28469263	126	135	arthritis	T047	C0003864
28469263	139	144	women	T098	C0043210
28469263	156	159	age	T032	C0001779
28469263	163	172	menopause	T039	C0025320
28469263	185	200	protective role	T078	C0086939
28469263	205	213	estrogen	T109,T121,T125	C0014939
28469263	217	220	LFJ	T030	C0507372
28469263	221	230	arthritis	T047	C0003864
28469263	250	261	no evidence	T080	C0332125
28469263	271	281	indication	T078	C3146298
28469263	290	299	mechanism	T169	C0441712
28469263	311	317	effect	T080	C1280500
28469263	353	358	study	T062	C2603343
28469263	360	385	ovariectomized (OVX) mice	T015	C0025929
28469263	409	417	estrogen	T109,T121,T125	C0014939
28469263	420	429	deficient	T169	C0011155
28469263	430	436	status	T080	C0449438
28469263	440	455	post-menopausal	T040	C0206159
28469263	456	461	women	T098	C0043210
28469263	463	471	Micro-CT	T060	C2350281
28469263	476	496	immunohistochemistry	T060	C0021044
28469263	513	519	assess	T058	C0184514
28469263	524	537	morphological	T082	C0543482
28469263	542	551	molecular	T080	C1521991
28469263	552	559	changes	T169	C0392747
28469263	563	574	ovariectomy	T061	C0029936
28469263	577	584	induced	T169	C0205263
28469263	585	588	LFJ	T030	C0507372
28469263	589	598	arthritis	T047	C0003864
28469263	604	611	results	T169	C1274040
28469263	626	629	LFJ	T030	C0507372
28469263	630	651	subchondral bone mass	T201	C0005938
28469263	670	679	decreased	T081	C0205216
28469263	683	691	OVX mice	T015	C0025929
28469263	698	707	increased	T081	C0205217
28469263	708	716	cavities	T030	C0229984
28469263	724	733	interface	T082	C1254362
28469263	741	757	subchondral bone	T023	C0262950
28469263	759	765	Severe	T080	C0205082
28469263	766	775	cartilage	T024	C0007301
28469263	776	787	degradation	T169	C0243125
28469263	804	815	ovariectomy	T061	C0029936
28469263	818	825	induced	T169	C0205263
28469263	826	829	LFJ	T030	C0507372
28469263	830	839	arthritis	T047	C0003864
28469263	841	850	Increased	T081	C0205217
28469263	851	864	blood vessels	T023	C0005847
28469263	869	881	innervations	T080	C1619351
28469263	901	912	degenerated	T046	C0011164
28469263	913	916	LFJ	T030	C0507372
28469263	938	954	subchondral bone	T023	C0262950
28469263	955	959	area	T029	C0005898
28469263	961	974	17β-Estradiol	T109,T121,T125	C0014912
28469263	975	984	treatment	T061	C0087111
28469263	997	1007	suppressed	T169	C1260953
28469263	1008	1011	LFJ	T030	C0507372
28469263	1012	1037	subchondral bone turnover	T033	C0231544
28469263	1048	1057	inhibited	T080	C0311403
28469263	1058	1067	cartilage	T024	C0007301
28469263	1068	1079	degradation	T169	C0243125
28469263	1085	1094	increased	T081	C0205217
28469263	1095	1107	blood vessel	T023	C0005847
28469263	1112	1124	nerve ending	T026	C0027747
28469263	1125	1131	growth	T040	C0018270
28469263	1135	1146	degenerated	T046	C0011164
28469263	1147	1150	LFJ	T030	C0507372
28469263	1154	1162	OVX mice	T015	C0025929
28469263	1168	1173	study	T062	C2603343
28469263	1187	1195	estrogen	T109,T121,T125	C0014939
28469263	1205	1211	factor	T169	C1521761
28469263	1215	1240	regulating LFJ metabolism	T169	C0518894
28469263	1242	1248	Severe	T080	C0205082
28469263	1249	1252	LFJ	T030	C0507372
28469263	1253	1265	degeneration	T046	C0011164
28469263	1278	1286	estrogen	T109,T121,T125	C0014939
28469263	1290	1296	absent	T169	C0332197
28469263	1297	1304	in vivo	T082	C1515655
28469263	1306	1315	Collapsed	T169	C0392748
28469263	1316	1332	subchondral bone	T023	C0262950
28469263	1344	1354	initiation	T169	C1704686
28469263	1363	1370	process	T067	C1522240
28469263	1376	1404	estrogen replacement therapy	T061	C0014935
28469263	1429	1441	degeneration	T046	C0011164
28469263	1445	1448	LFJ	T030	C0507372
28469263	1455	1463	estrogen	T109,T121,T125	C0014939
28469263	1466	1475	deficient	T169	C0011155
28469263	1476	1486	conditions	T080	C0348080